Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Pass Below 200 Day Moving Average – Here’s What Happened

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.95 and traded as low as $29.19. Lakefront Biotherapeutics American Depositary Shares shares last traded at $29.67, with a volume of 122,618 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LKFT shares. Wall Street Zen lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings restated a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, May 26th. Finally, Zacks Research raised shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.50.

Lakefront Biotherapeutics American Depositary Shares Price Performance

The stock has a 50-day simple moving average of $28.20 and a 200-day simple moving average of $30.95. The stock has a market cap of $1.96 billion, a PE ratio of -21.04 and a beta of 0.26.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last announced its quarterly earnings results on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The firm had revenue of $1.06 billion for the quarter. As a group, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 EPS for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of institutional investors and hedge funds have recently bought and sold shares of LKFT. ABC Arbitrage SA purchased a new position in Lakefront Biotherapeutics American Depositary Shares in the first quarter valued at approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Lakefront Biotherapeutics American Depositary Shares during the first quarter worth approximately $248,000. QRG Capital Management Inc. grew its stake in Lakefront Biotherapeutics American Depositary Shares by 21.9% during the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares during the period. XTX Topco Ltd increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 92.6% in the fourth quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock worth $759,000 after acquiring an additional 11,162 shares in the last quarter. Finally, Millennium Management LLC increased its position in shares of Lakefront Biotherapeutics American Depositary Shares by 121.9% in the fourth quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock worth $11,097,000 after acquiring an additional 186,452 shares in the last quarter. Institutional investors and hedge funds own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.